AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29029616 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-management intervention guided by peer-trainers
Number of subjects: 72
Study 29029616 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 72
Study 25940329 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% glucose in water solution (group G5W)
Number of subjects: 91
Study 25940329 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.33% glucose in 0.3% NaCl (group GNaCl)
Number of subjects: 91
Study 25940329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's acetate (group RA)
Number of subjects: 91
Study 23044342 — intervention group
Group type: EXPERIMENTAL
Intervention: Puerarin (PUE)
Number of subjects: 0
Study 23044342 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 0
Study 22068140 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgotul Trio
Number of subjects: 0
Study 22068140 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepilex Border
Number of subjects: 0
Study 22068140 — intervention group
Group type: EXPERIMENTAL
Intervention: Allevyn Adhesive
Number of subjects: 0
Study 22068140 — intervention group
Group type: EXPERIMENTAL
Intervention: Versiva XC
Number of subjects: 0
Study 22068140 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfeel Plus
Number of subjects: 0
Study 22068140 — intervention group
Group type: EXPERIMENTAL
Intervention: Biatain
Number of subjects: 0
Study 22068140 — intervention group
Group type: COMPARATOR
Intervention: Untreated area
Number of subjects: 0
Study 19968380 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) with more than 9 sessions
Number of subjects: 334
Study 19968380 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) with problem-solving treatment component
Number of subjects: 334
Study 19968380 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) with social skills treatment component
Number of subjects: 334
Study 17699181 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous carotid stenting
Number of subjects: 0
Study 17699181 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical carotid endarterectomy
Number of subjects: 0
Study 17699181 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor management
Number of subjects: 0
Study 15447898 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg folic acid in a tablet
Number of subjects: 96
Study 15447898 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg natural folate provided as spinach
Number of subjects: 96
Study 15447898 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg natural folate provided as yeast
Number of subjects: 96
Study 15447898 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 96
Study 11489002 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 25
Study 11489002 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine-cisplatin
Number of subjects: 25
Study 11489002 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine-paclitaxel
Number of subjects: 25
Study 11489002 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and gemcitabine (first-line treatment)
Number of subjects: 25
Study 11489002 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine, paclitaxel, and cisplatin or carboplatin (triplet therapy)
Number of subjects: 25
Study 11489002 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine, paclitaxel, and carboplatin (combination treatment)
Number of subjects: 25
Study 9541344 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and fentanyl (P + F)
Number of subjects: 57
Study 9541344 — intervention group
Group type: COMPARATOR
Intervention: Midazolam and fentanyl (M + F)
Number of subjects: 57
Study 7999652 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene block
Number of subjects: 508
Study 7999652 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary block
Number of subjects: 508
Study 7999652 — intervention group
Group type: COMPARATOR
Intervention: Transarterial approach for axillary block
Number of subjects: 508
Study 7999652 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 508
Study 3421208 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-100 g linseed oil
Number of subjects: 0
Study 3421208 — intervention group
Group type: EXPERIMENTAL
Intervention: linolenic acid absorption
Number of subjects: 0
Study 3421208 — intervention group
Group type: EXPERIMENTAL
Intervention: mouth-to-ileum transit time
Number of subjects: 0
Study 29326318 — intervention group
Group type: EXPERIMENTAL
Intervention: ELTGOL technique
Number of subjects: 44
Study 29326318 — intervention group
Group type: COMPARATOR
Intervention: Placebo exercises
Number of subjects: 44
Study 27914501 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous levosimendan (0.2 μg kg‐1 min‐1 for the first hour followed by 0.1 μg/kg for 23 hours)
Number of subjects: 880
Study 27914501 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 880
Study 24180327 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced calibration of CGM device (calibrated at variable intervals of 1-6 hours using ABG)
Number of subjects: 24
Study 24180327 — intervention group
Group type: COMPARATOR
Intervention: Standard calibration of CGM device (calibrated according to manufacturer's instructions at 1, 2, 10, and 24 hours)
Number of subjects: 24
Study 22013887 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-wave insulin boluses for pizza dinner (45g carbohydrates, 400kcal from fat-protein)
Number of subjects: 24
Study 22013887 — intervention group
Group type: COMPARATOR
Intervention: Control group using standard insulin dose calculation (n Carbohydrate Units×ICR)
Number of subjects: 24
Study 20711065 — intervention group
Group type: EXPERIMENTAL
Intervention: Early physical and occupational therapy (daily sedative interruption followed by therapy every hospital day)
Number of subjects: 49
Study 19145732 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft diet
Number of subjects: 101
Study 19145732 — intervention group
Group type: COMPARATOR
Intervention: Clear liquid diet
Number of subjects: 101
Study 16351775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate syrup (20 mg elemental Fe twice daily) + single dose of vitamin A (33,000 microg)
Number of subjects: 169
Study 16351775 — intervention group
Group type: COMPARATOR
Intervention: Placebo + single dose of vitamin A (33,000 microg)
Number of subjects: 169
Study 12438295 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blockers
Number of subjects: 2096
Study 12438295 — intervention group
Group type: COMPARATOR
Intervention: no beta-blockers
Number of subjects: 2096
Study 10876850 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated inactivated tissue-culture tick-borne encephalitis vaccine
Number of subjects: 0
Study 8607736 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback treatment (one 45-minute session)
Number of subjects: 100
Study 8607736 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional biofeedback treatment sessions (average of 3 sessions)
Number of subjects: 100
Study 2013954 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-based care (2 years)
Number of subjects: 0
Study 2013954 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 0
Study 7322958 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 0
Study 7322958 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 0
Study 31977638 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 20
Study 31977638 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 20
Study 31088522 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep duration (< 7 hours)
Number of subjects: 62517
Study 31088522 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep duration (< 7 hours) for boys (6-12 years and 13-17 years)
Number of subjects: 62517
Study 31088522 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep duration (< 7 hours) for older girls (13-17 years)
Number of subjects: 62517
Study 28070957 — intervention group
Group type: EXPERIMENTAL
Intervention: Hartmann's solution (HS)
Number of subjects: 77
Study 28070957 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 77
Study 25592188 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity WBV (peak acceleration=0.96g)
Number of subjects: 48
Study 25592188 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity WBV (peak acceleration=1.61g)
Number of subjects: 48
Study 25592188 — intervention group
Group type: COMPARATOR
Intervention: Control (no WBV)
Number of subjects: 48
Study 25592188 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity WBV
Number of subjects: 48
Study 25592188 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity WBV
Number of subjects: 48
Study 25592188 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity WBV and High-intensity WBV
Number of subjects: 48
Study 25627184 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric intraocular lens (Akreos AO)
Number of subjects: 25
Study 25627184 — intervention group
Group type: COMPARATOR
Intervention: Spherical intraocular lens (Akreos Fit)
Number of subjects: 25
Study 21075062 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation powder (TIP™) - 112mg via Novartis T‐326 Inhaler
Number of subjects: 553
Study 21075062 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin inhalation solution (TIS, TOBI®) - 300mg/5mL via PARI LC® PLUS nebulizer
Number of subjects: 553
Study 21075062 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation powder (TIP™)
Number of subjects: 553
Study 21075062 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin inhalation solution (TIS, TOBI®)
Number of subjects: 553
Study 19887042 — intervention group
Group type: EXPERIMENTAL
Intervention: GrHu group (multisensory training approach)
Number of subjects: 40
Study 19887042 — intervention group
Group type: COMPARATOR
Intervention: GrCl group (classical rehabilitation protocol)
Number of subjects: 40
Study 18246982 — intervention group
Group type: EXPERIMENTAL
Intervention: Indiplon 10 mg
Number of subjects: 264
Study 18246982 — intervention group
Group type: EXPERIMENTAL
Intervention: Indiplon 20 mg
Number of subjects: 264
Study 18246982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 15724223 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease Management Programme (DMP)
Number of subjects: 0
Study 15724223 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 12468450 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (immunosuppressive drug) paired with a distinctively flavored drink (conditioned stimulus)
Number of subjects: 0
Study 12468450 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules paired with the conditioned stimulus (drink)
Number of subjects: 0
Study 9475269 — intervention group
Group type: EXPERIMENTAL
Intervention: molsidomine retard, 8 mg b.i.d.
Number of subjects: 90
Study 9475269 — intervention group
Group type: EXPERIMENTAL
Intervention: molsidomine, 4 mg t.i.d.
Number of subjects: 90
Study 7609572 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous retrograde warm blood cardioplegia
Number of subjects: 21
Study 7609572 — intervention group
Group type: COMPARATOR
Intervention: Continuous retrograde mild hypothermic blood cardioplegia
Number of subjects: 21
Study 2797640 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (3 doses of 1-g intravenous cefazolin before, during, and 6-8 hours after surgery)
Number of subjects: 26
Study 2797640 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic antibiotics)
Number of subjects: 26
Study 382158 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 5
Study 30898520 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation
Number of subjects: 313
Study 30898520 — intervention group
Group type: COMPARATOR
Intervention: High-flow oxygen therapy
Number of subjects: 313
Study 30153753 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 92
Study 30153753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 27017776 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegadarm comfort film dressing with aron alpha A [Sankyo] (TA group)
Number of subjects: 20
Study 27017776 — intervention group
Group type: COMPARATOR
Intervention: Tegadarm film (T group)
Number of subjects: 20
Study 25147030 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 691
Study 25147030 — intervention group
Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 691
Study 22984831 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing the public behavior of a randomly assigned subset of student social referents
Number of subjects: 0
Study 22984831 — intervention group
Group type: EXPERIMENTAL
Intervention: Social referents' public behavior
Number of subjects: 0
Study 22984831 — intervention group
Group type: COMPARATOR
Intervention: Interaction shaped by institutional channels like shared classes
Number of subjects: 0
Study 18625521 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 278
Study 18625521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 17575465 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined program of aquatic exercise plus high-intensity strength training (group 1)
Number of subjects: 62
Study 17575465 — intervention group
Group type: COMPARATOR
Intervention: Combined program of aquatic exercise plus calisthenic training (group 2)
Number of subjects: 62
Study 15379051 — intervention group
Group type: EXPERIMENTAL
Intervention: Verorab vaccine (3 intramuscular doses at days 0, 7, and 28)
Number of subjects: 54
Study 15379051 — intervention group
Group type: COMPARATOR
Intervention: CRL vaccine (4 subcutaneous doses at days 0, 3, 7, and 28)
Number of subjects: 54
Study 11803988 — intervention group
Group type: EXPERIMENTAL
Intervention: Battery-operated power toothbrush (Dr. Johns Spin Brush Classic)
Number of subjects: 0
Study 11803988 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (ADA toothbrush)
Number of subjects: 0
Study 11803988 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (CrossAction toothbrush)
Number of subjects: 0
Study 9580255 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha2b, 5 million units, subcutaneously daily for 16 weeks
Number of subjects: 23
Study 9580255 — intervention group
Group type: COMPARATOR
Intervention: Prednisone for a total of six weeks prior to interferon starting at 60 mg daily with reduction in dosage by 20 mg every two weeks
Number of subjects: 23
Study 9580255 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha2b
Number of subjects: 23
Study 7973768 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy and radiation therapy followed by resection
Number of subjects: 0
Study 7973768 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Number of subjects: 0
Study 7973768 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus vinorelbine
Number of subjects: 0
Study 7973768 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and vinorelbine
Number of subjects: 0
Study 7973768 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 0
Study 3057852 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide 150 mg 4 times a day
Number of subjects: 10
Study 3057852 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 40 mg 4 times a day
Number of subjects: 10
Study 30842721 — intervention group
Group type: EXPERIMENTAL
Intervention: simBiCI group
Number of subjects: 38
Study 30842721 — intervention group
Group type: COMPARATOR
Intervention: UCI/seqBiCI group
Number of subjects: 38
Study 28428187 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct distribution of HIV self-test (HIVST) from peer educator
Number of subjects: 900
Study 28428187 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed distribution of a coupon to collect HIVST from a drug store or health post
Number of subjects: 900
Study 28428187 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (referral to existing HIV testing services only, without any offer of HIVST)
Number of subjects: 900
Study 25891173 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab every 2 weeks
Number of subjects: 834
Study 25891173 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab every 3 weeks
Number of subjects: 834
Study 25891173 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 834
Study 22782539 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg loading dose with dabigatran etexilate 150 mg bid (part 1)
Number of subjects: 20
Study 22782539 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg loading dose with dabigatran etexilate 150 mg bid (part 3)
Number of subjects: 20
Study 22782539 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg qd with dabigatran etexilate 150 mg bid (part 2)
Number of subjects: 20
Study 21496674 — intervention group
Group type: EXPERIMENTAL
Intervention: ZOE-based sealer with powder/liquid ratio of 1:2
Number of subjects: 50
Study 21496674 — intervention group
Group type: EXPERIMENTAL
Intervention: ZOE-based sealer with powder/liquid ratio of 1:3
Number of subjects: 50
Study 21496674 — intervention group
Group type: COMPARATOR
Intervention: Gutta-percha alone (control group)
Number of subjects: 50
Study 21496674 — intervention group
Group type: EXPERIMENTAL
Intervention: ZOE-based sealer with powder/liquid ratio of 1:1
Number of subjects: 50
Study 21496674 — intervention group
Group type: EXPERIMENTAL
Intervention: ZOE-based sealer with powder/liquid ratio of 1:4
Number of subjects: 50
Study 18463543 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga therapy (surya namaskara, pranayama, avartan dhyan)
Number of subjects: 120
Study 18463543 — intervention group
Group type: COMPARATOR
Intervention: Control group (simple physical exercises)
Number of subjects: 120
Study 16129526 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal proteosome‐adjuvanted vaccine
Number of subjects: 2
Study 16129526 — intervention group
Group type: COMPARATOR
Intervention: Intranasal saline
Number of subjects: 2
Study 14498756 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 or 20 mg (on-demand, not more than once daily)
Number of subjects: 0
Study 14498756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16394324 — intervention group
Group type: COMPARATOR
Intervention: Bolus priming (10 microg/kg)
Number of subjects: 112
Study 16394324 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming infusion (5 microg/kg/min) for vecuronium (15 microg/kg)
Number of subjects: 112
Study 16394324 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher priming infusion (10 microg/kg/min) for vecuronium (15 microg/kg)
Number of subjects: 112
Study 16394324 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming infusion (10 microg/kg/min) for vecuronium (20 microg/kg)
Number of subjects: 112
Study 10599981 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (HFD)
Number of subjects: 16
Study 10599981 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 16
Study 8609288 — intervention group
Group type: COMPARATOR
Intervention: Normal-hearing listeners
Number of subjects: 14
Study 8609288 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing-impaired listeners
Number of subjects: 14
Study 1783914 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg twice daily (n = 815)
Number of subjects: 2435
Study 1783914 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg once daily (n = 806)
Number of subjects: 2435
Study 1783914 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 814)
Number of subjects: 2435
Study 7015129 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 18
Study 7015129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31409421 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral HIV self-testing (HIVST) provided for eligible household members who are absent or decline testing.
Number of subjects: 0
Study 31409421 — intervention group
Group type: COMPARATOR
Intervention: Standard of care for absent and refusing individuals (referral to a health facility).
Number of subjects: 0
Study 29275344 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus a 12-week cardiovascular rehabilitation programme (60 min of education plus two 60 min aerobic exercise sessions/week at 60%-80% of heart rate reserve)
Number of subjects: 60
Study 29275344 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) treatment
Number of subjects: 60
Study 24954016 — intervention group
Group type: EXPERIMENTAL
Intervention: High-voltage pulsed radiofrequency (PRFT)
Number of subjects: 60
Study 24954016 — intervention group
Group type: COMPARATOR
Intervention: Standard-voltage pulsed radiofrequency (PRFT)
Number of subjects: 60
Study 24417760 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC)
Number of subjects: 43
Study 24417760 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (CC)
Number of subjects: 43
Study 22488613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented Exeter implant
Number of subjects: 160
Study 22488613 — intervention group
Group type: COMPARATOR
Intervention: Uncemented Zweymüller Alloclassic implant
Number of subjects: 160
Study 19525856 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg/day
Number of subjects: 26
Study 19525856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 18163098 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic apical periodontitis (CAP) involving not more than 2 teeth
Number of subjects: 0
Study 18163098 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic apical periodontitis (CAP) involving plural CAP
Number of subjects: 0
Study 18163098 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic inflammation course in periodontal tissues
Number of subjects: 0